upadacitinib

Mon, 21 Mar 2022 14:38:46 -0400
For the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, loss of response to, or were intolerant to either conventional therapy or a biologic agent (i.e., tumour necrosis factor-alpha [TNFα] antagonists, integrin receptor antagonists or interleukin 12/23 inhibitors).